<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03503461</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2018/08</org_study_id>
    <nct_id>NCT03503461</nct_id>
  </id_info>
  <brief_title>Major Activation Of NCC in Graft Urinary Exosomes</brief_title>
  <acronym>MANGUE</acronym>
  <official_title>Evaluation of the Prevalence of an Hyperactivation of NCC Cotransporter Three Months After Kidney Transplantation in Recipients Treated by Calcineurin Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertension is common disorder after renal transplantation and is associated with mortality.
      Calcineurin Inhibitor (CNI), by activating NCC cotransporter, may be a major determinant of
      hypertension, included in a &quot;Gordon like&quot; syndrome. However, prevalence of NCC activation by
      CNI is unknown. Our objective is to determine the prevalence of NCC activation three months
      after transplantation in patient treated by CNI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertension is common disorder after renal transplantation and is associated with mortality.
      Calcineurin Inhibitor (CNI), by activating NCC cotransporter, may be a major determinant of
      hypertension, included in a &quot;Gordon like&quot; syndrome. Gordon syndrome is a rare genetic
      disorder where NCC cotransporter is overactivated and cause hypertension, metabolic acidosis
      and tendency to hyperkaliemia. Few studies evaluated NCC expression by exosomes techniques in
      human kidney transplant, and mostly compared NCC expression in specific subpopulation (for
      example with or without hypertension). Thus, prevalence of NCC activation by CNI is unknown.
      To determine it, we will include prospective patients in Bordeaux and la Réunion who undergo
      urine and blood tests three months after transplantation, and a control group with no
      transplantation and no use of CNI. First, we will compare kidney recipients and control and
      use immunoblot to quantify NCC expression in urinary exosomes to identify the population of
      transplanted with a high activation. Then, we will analyze the relationship between NCC
      activation and clinicobiological features of Gordon's syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>NCC cotransporter expression</measure>
    <time_frame>Inclusion day</time_frame>
    <description>Dosage of NCC cotransporter expression in urinary exosomes samples in both groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phosphorylated NCC cotransporter expression</measure>
    <time_frame>Inclusion day</time_frame>
    <description>Dosage of phosphorylated NCC cotransporter expression in urinary exosomes samples in both groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pendrine expression in kidney transplant group</measure>
    <time_frame>Inclusion day</time_frame>
    <description>Dosage of pendrine expression in urinary exosomes samples in kidney transplant group.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Control group is a population of subjects admitted to day hospitalization for renal function tests or in conventional hospitalization, but without kidney transplant. Exosome analysis will be perform in urine sample.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kidney transplants group</arm_group_label>
    <description>Kidney transplants group is a kidney transplant subjects population 3 months ago. Exosome analysis will be perform in urine sample collected at 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>exosomes analysis</intervention_name>
    <description>Perform exosomes analysis in urine sample obtain from usual urine testing in both kidney transplant and control group.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Kidney transplants group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Kidney transplant group is a population of transplant subjects treated with anticalcineurin
        since 3 months.

        Control group is a population of subjects admitted to day hospitalization for renal
        function tests or in conventional hospitalization, but without kidney transplant.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For kidney transplant group :

          -  inclusion criteria:

               -  Age≥18years

               -  Recipients three months after kidney transplantation using calcineurin inhibitors

               -  Glomerular Filtration Rate&gt;15ml.mn.m2 CKD-EPI

               -  Renal ultrasound underwent before inclusion

               -  No opposition at participating at the research

          -  exclusion criteria:

               -  Use of diuretic thiazides or aldosterone receptor antagonists in the month
                  preceding inclusion

               -  Graft artery stenosis with indication of interventional radiology or surgery

        For control group :

          -  Inclusion criteria

               -  No previous transplantation

               -  Age≥18years

               -  No hypertension

               -  No metabolic disorders (dysnatremia, dyskaliemia, acidosis or alkalosis)

               -  No opposition at participating at the research

          -  Exclusion criteria:

               -  Use of diuretic thiazides or aldosterone receptor antagonists in the month
                  preceding inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>DI ASCIA Ludovic</last_name>
    <phone>0692025924</phone>
    <email>ludidias@hotmail.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>COUZI Lionel, Pr</last_name>
    <phone>0556795538</phone>
    <phone_ext>+33</phone_ext>
    <email>lionel.couzi@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Pellegrin - Service Néphrologie, transplantation, dialyse et aphérèse</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>DI ASCIA Ludovic</last_name>
      <phone>0692025924</phone>
      <email>ludidias@hotmail.fr</email>
    </contact>
    <investigator>
      <last_name>Couzi Lionel, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Felix Guyon - Service d'Explorations Fonctionnelles Rénales</name>
      <address>
        <city>Saint-Denis</city>
        <zip>97400</zip>
        <country>Réunion</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>DI ASCIA Ludovic</last_name>
      <phone>0692025924</phone>
      <email>ludidias@hotmail.fr</email>
    </contact>
    <investigator>
      <last_name>ELADARI Dominique, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Réunion</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2018</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Calcineurin inhibitors</keyword>
  <keyword>hypertension</keyword>
  <keyword>kidney transplant</keyword>
  <keyword>acidosis</keyword>
  <keyword>Gordon syndrome</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

